Since the discovery of the cardiac hormone ANP, the field of natriuretic peptides has significantly advanced with translation of new knowledge to the clinical practice of heart failure (HF). This new knowledge has underscored the importance of cardiorenal mechanisms that contribute to optimal cardiovascular homeostasis. Work has also established direct myocardial actions broadening their therapeutic potential beyond renal mechanisms. Indeed, one such therapeutic target is cardiac remodeling and fibrosis based upon the unique cardiorenal protective properties. The objective of this article is to review new insights into the use of natriuretic peptides as novel therapeutic agents for cardiorenal protection in progressive HF, which serves to limit cardiac remodeling and fibrosis and thus the progression of HF.
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine